» Articles » PMID: 7923988

Mammary Carcinoma Cell Lines of High and Low Metastatic Potential Differ Not in Extravasation but in Subsequent Migration and Growth

Overview
Specialty Oncology
Date 1994 Nov 1
PMID 7923988
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the extravasation and subsequent migration and growth of murine mammary tumor cell lines (D2A1 and D2.OR) which differ in their metastatic ability in lung and liver, invasiveness in vitro and expression of the cysteine proteinase cathepsin L. In light of the differences in invasiveness and cathepsin L expression, we hypothesized that during hematogenous metastasis the two cell lines would differ primarily in their ability to extravasate. We used in vivo videomicroscopy of mouse liver and chick embryo chorioallantoic membrane to examine the process and timing of extravasation and subsequent steps in metastasis for these cell lines. In contrast to our expectations, no differences were found between the cell lines in either the timing or mechanism of extravasation, at least 95% of cells having extravasated by 3 days after injection. However, after extravasation, the more metastatic and invasive D2A1 cells showed a greater ability to migrate to sites which favor tumor growth and to replicate to form micrometastases. These studies point to post-extravasation events (migration and growth) as being critical in metastasis formation.

Citing Articles

De novo lipogenesis protects dormant breast cancer cells from ferroptosis and promotes metastasis.

Puente-Cobacho B, Esteo C, Altea-Manzano P, Garcia-Perez J, Quiles J, Sanchez-Rovira P Redox Biol. 2025; 80:103480.

PMID: 39787900 PMC: 11764609. DOI: 10.1016/j.redox.2024.103480.


Autophagy is required for mammary tumor recurrence by promoting dormant tumor cell survival following therapy.

Dwyer S, Ruth J, Seidel H, Raz A, Chodosh L Breast Cancer Res. 2024; 26(1):143.

PMID: 39425240 PMC: 11488247. DOI: 10.1186/s13058-024-01878-7.


Therapy-induced normal tissue damage promotes breast cancer metastasis.

Perkins D, Steiner I, Haider S, Robertson D, Buus R, OLeary L iScience. 2024; 27(1):108503.

PMID: 38161426 PMC: 10755366. DOI: 10.1016/j.isci.2023.108503.


B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.

Sreekumar A, Lu M, Choudhury B, Pan T, Pant D, Lawrence-Paul M Cancer Cell. 2023; 42(1):52-69.e7.

PMID: 38065100 PMC: 10872305. DOI: 10.1016/j.ccell.2023.11.008.


Dormancy in Breast Cancer.

Dalla E, Sreekumar A, Aguirre-Ghiso J, Chodosh L Cold Spring Harb Perspect Med. 2023; 13(11.

PMID: 37037598 PMC: 10562521. DOI: 10.1101/cshperspect.a041331.


References
1.
Koop S, Khokha R, Schmidt E, MacDonald I, Morris V, Chambers A . Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 1994; 54(17):4791-7. View

2.
Chambers A, Wilson S . Use of NeoR B16F1 murine melanoma cells to assess clonality of experimental metastases in the immune-deficient chick embryo. Clin Exp Metastasis. 1988; 6(2):171-82. DOI: 10.1007/BF01784847. View

3.
Aznavoorian S, Murphy A, Stetler-Stevenson W, Liotta L . Molecular aspects of tumor cell invasion and metastasis. Cancer. 1993; 71(4):1368-83. DOI: 10.1002/1097-0142(19930215)71:4<1368::aid-cncr2820710432>3.0.co;2-l. View

4.
Liotta L . Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986; 46(1):1-7. View

5.
MacDonald I, Schmidt E, Morris V, Chambers A, Groom A . Intravital videomicroscopy of the chorioallantoic microcirculation: a model system for studying metastasis. Microvasc Res. 1992; 44(2):185-99. DOI: 10.1016/0026-2862(92)90079-5. View